Literature DB >> 28940010

Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes.

Balázs Horváth1,2, Norbert Szentandrássy1,3, Roland Veress1, János Almássy1, János Magyar1,4, Tamás Bányász1, Attila Tóth5, Zoltán Papp5, Péter P Nánási6,7.   

Abstract

Omecamtiv mecarbil (OM) is a myosin activator agent developed for the treatment of heart failure. OM was reported to increase left ventricular ejection fraction and systolic ejection time, but little is known about the effect of heart rate on the action of OM. The present study, therefore, was designed to investigate the effects of OM on unloaded cell shortening and intracellular Ca2+ ([Ca2+]i) transients as a function of the pacing frequency. Isolated cardiomyocytes were stimulated at various frequencies under steady-state conditions. Cell length was monitored by an optical edge detector and changes in [Ca2+]i were followed using the Ca2+-sensitive dye Fura-2. At the pacing frequency of 1 Hz, OM (1-10 μM) significantly decreased both diastolic and systolic cell length, however, fractional shortening was augmented only by 1 μM OM. Time to peak tension and time of 90% relaxation were progressively increased by OM. At the frequency of 2 Hz, diastolic cell length was reduced by 10 μM OM to a larger extent than systolic cell length, resulting in a significantly decreased fractional shortening under these conditions. OM had no effect on the parameters of the [Ca2+]i transient at any pacing frequency. The results suggest that supratherapeutic concentrations of OM may decrease rather than increase the force of cardiac contraction especially in tachycardic patients.

Entities:  

Keywords:  Cardiac myocytes; Cell shortening; Cytosolic Ca2+; Myosin activators; Omecamtiv mecarbil

Mesh:

Substances:

Year:  2017        PMID: 28940010     DOI: 10.1007/s00210-017-1422-z

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  29 in total

1.  9-Anthracene carboxylic acid is more suitable than DIDS for characterization of calcium-activated chloride current during canine ventricular action potential.

Authors:  Krisztina Váczi; Bence Hegyi; Ferenc Ruzsnavszky; Kornél Kistamás; Balázs Horváth; Tamás Bányász; Péter P Nánási; Norbert Szentandrássy; János Magyar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-10-26       Impact factor: 3.000

2.  The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat.

Authors:  L Nagy; Á Kovács; B Bódi; E T Pásztor; G Á Fülöp; A Tóth; I Édes; Z Papp
Journal:  Br J Pharmacol       Date:  2015-08-04       Impact factor: 8.739

3.  Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.

Authors:  John R Teerlink; G Michael Felker; John J V McMurray; Piotr Ponikowski; Marco Metra; Gerasimos S Filippatos; Justin A Ezekowitz; Kenneth Dickstein; John G F Cleland; Jae B Kim; Lei Lei; Beat Knusel; Andrew A Wolff; Fady I Malik; Scott M Wasserman
Journal:  J Am Coll Cardiol       Date:  2016-03-29       Impact factor: 24.094

4.  Dose-dependent electrophysiological effects of the myosin activator omecamtiv mecarbil in canine ventricular cardiomyocytes.

Authors:  N Szentandrassy; B Horvath; K Vaczi; K Kistamas; L Masuda; J Magyar; T Banyasz; Z Papp; P P Nanasi
Journal:  J Physiol Pharmacol       Date:  2016-08       Impact factor: 3.011

5.  The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

Authors:  John G F Cleland; John R Teerlink; Roxy Senior; Evgeny M Nifontov; John J V Mc Murray; Chim C Lang; Vitaly A Tsyrlin; Barry H Greenberg; Jamil Mayet; Darrel P Francis; Tamaz Shaburishvili; Mark Monaghan; Mitchell Saltzberg; Ludwig Neyses; Scott M Wasserman; Jacqueline H Lee; Khalil G Saikali; Cyril P Clarke; Jonathan H Goldman; Andrew A Wolff; Fady I Malik
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

6.  Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.

Authors:  John R Teerlink; Cyril P Clarke; Khalil G Saikali; Jacqueline H Lee; Michael M Chen; Rafael D Escandon; Lyndsey Elliott; Rachel Bee; Mohammad Reza Habibzadeh; Jonathan H Goldman; Nelson B Schiller; Fady I Malik; Andrew A Wolff
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

7.  Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.

Authors:  You-Tang Shen; Fady I Malik; Xin Zhao; Christophe Depre; Sunil K Dhar; Patricio Abarzúa; David J Morgans; Stephen F Vatner
Journal:  Circ Heart Fail       Date:  2010-05-24       Impact factor: 8.790

8.  Effects of tacrolimus on action potential configuration and transmembrane ion currents in canine ventricular cells.

Authors:  László Szabó; Norbert Szentandrássy; Kornél Kistamás; Bence Hegyi; Ferenc Ruzsnavszky; Krisztina Váczi; Balázs Horváth; János Magyar; Tamás Bányász; Balázs Pál; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-19       Impact factor: 3.000

9.  Mouse intact cardiac myocyte mechanics: cross-bridge and titin-based stress in unactivated cells.

Authors:  Nicholas M P King; Methajit Methawasin; Joshua Nedrud; Nicholas Harrell; Charles S Chung; Michiel Helmes; Henk Granzier
Journal:  J Gen Physiol       Date:  2011-01       Impact factor: 4.086

10.  Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects.

Authors:  Rameshraja Palaparthy; Christopher Banfield; Paco Alvarez; Lucy Yan; Brian Smith; Jessica Johnson; Maria Laura Monsalvo; Fady Malik
Journal:  Int J Clin Pharmacol Ther       Date:  2016-03       Impact factor: 1.366

View more
  12 in total

1.  A Microwell Cell Capture Device Reveals Variable Response to Dobutamine in Isolated Cardiomyocytes.

Authors:  J Alexander Clark; Jonathan D Weiss; Stuart G Campbell
Journal:  Biophys J       Date:  2019-08-28       Impact factor: 4.033

2.  Effects of omecamtiv mecarbil on calcium-transients and contractility in a translational canine myocyte model.

Authors:  BaoXi Gao; Weston Sutherland; Hugo M Vargas; Yusheng Qu
Journal:  Pharmacol Res Perspect       Date:  2020-10

Review 3.  Shock - Classification and Pathophysiological Principles of Therapeutics.

Authors:  Olga N Kislitsina; Jonathan D Rich; Jane E Wilcox; Duc T Pham; Andrei Churyla; Esther B Vorovich; Kambiz Ghafourian; Clyde W Yancy
Journal:  Curr Cardiol Rev       Date:  2019

Review 4.  The Control of Diastolic Calcium in the Heart: Basic Mechanisms and Functional Implications.

Authors:  David A Eisner; Jessica L Caldwell; Andrew W Trafford; David C Hutchings
Journal:  Circ Res       Date:  2020-01-30       Impact factor: 17.367

5.  Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans.

Authors:  Gábor Á Fülöp; Attila Oláh; Tamas Csipo; Tamás Radovits; Attila Tóth; Árpád Kovács; Róbert Pórszász; Roland Veress; Balázs Horváth; László Nagy; Beáta Bódi; Miklós Fagyas; Solveig Lind Helgadottir; Viktor Bánhegyi; Béla Juhász; Mariann Bombicz; Daniel Priksz; Peter Nanasi; Béla Merkely; István Édes; Zoltán Csanádi; Zoltán Papp
Journal:  Basic Res Cardiol       Date:  2021-04-12       Impact factor: 17.165

6.  Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline.

Authors:  Alexander Dashwood; Elizabeth Cheesman; Yee Weng Wong; Haris Haqqani; Nicole Beard; Karen Hay; Melanie Spratt; Wandy Chan; Peter Molenaar
Journal:  Pharmacol Res Perspect       Date:  2021-05

7.  Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action.

Authors:  Jaimit Parikh; Timothy Rumbell; Xenia Butova; Tatiana Myachina; Jorge Corral Acero; Svyatoslav Khamzin; Olga Solovyova; James Kozloski; Anastasia Khokhlova; Viatcheslav Gurev
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-10-29       Impact factor: 2.745

8.  Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke.

Authors:  Michael S Woody; Michael J Greenberg; Bipasha Barua; Donald A Winkelmann; Yale E Goldman; E Michael Ostap
Journal:  Nat Commun       Date:  2018-09-21       Impact factor: 14.919

9.  Simultaneous measurement of excitation-contraction coupling parameters identifies mechanisms underlying contractile responses of hiPSC-derived cardiomyocytes.

Authors:  Berend J van Meer; Ana Krotenberg; Luca Sala; Richard P Davis; Thomas Eschenhagen; Chris Denning; Leon G J Tertoolen; Christine L Mummery
Journal:  Nat Commun       Date:  2019-09-20       Impact factor: 14.919

10.  Force and Calcium Transients Analysis in Human Engineered Heart Tissues Reveals Positive Force-Frequency Relation at Physiological Frequency.

Authors:  Umber Saleem; Ingra Mannhardt; Ingke Braren; Chris Denning; Thomas Eschenhagen; Arne Hansen
Journal:  Stem Cell Reports       Date:  2020-01-16       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.